News & Updates

Evinacumab hits mark in difficult-to-treat children with rare lipid disorder

The angiopoietin-like 3 inhibitor evinacumab appears to reduce low-density lipoprotein cholesterol (LDL-C) levels in children with homozygous familial hypercholesterolemia (HoFH) and persistently high LDL-C despite optimized therapy.

Robust evidence for fenofibrate in patients with metabolic syndrome on statins

Young men with overweight, obesity at greater risk of developing cancer

Higher body mass index (BMI) may increase the risk of developing site-specific cancers in young men, reveals a recent study.

Overweight, obesity fuel risk of developing cardiopulmonary multimorbidity

Being fat contributes to the development of cardiopulmonary (CP) multimorbidity (MM), reports a study. As a result, adiposity may be targeted by future interventions to help prevent MM.

Young-onset T2D tied to elevated risk of heart failure hospitalization

Individuals who received a diagnosis of type 2 diabetes (T2D) at a young age appear to have a disproportionately increased risk of hospitalization for heart failure (HF), according to a study.

13 biomarkers predict CVD risk in T2DM

An international team of experts has identified 13 promising biomarkers to predict cardiovascular disease (CVD) risk in patients with type 2 diabetes mellitus (T2DM), of which N-terminal pro-brain natriuretic peptide (NT-proBNP) has shown the highest predictive utility with highest strength of evidence.

GnRHa therapy does not decrease BMD in children with congenital adrenal hyperplasia

Gonadotropin-releasing hormone analogue (GnRHa) therapy is not responsible for the reduction in bone mineral density (BMD) among children with congenital adrenal hyperplasia (CAH), reports a study